ALS Matrix is using AI and advanced computational biology to understand why some neurones survive in ALS while others don’t. By mapping the gene networks that protect resilient neurones, the team is aiming to identify new drug targets whose modulation could slow or stop the disease’s progression.

ALS Matrix is a partnership between Aperture Therapeutics (USA), Harvard Medical School and Tufts University.

The ALS-AIM Consortium is training an AI that reads the genes, molecules and clinical information records of thousands of patients at once, finds the hidden patterns and points scientists towards new drugs that could help.

The ALS-AIM Consortium is a partnership between Boston University (USA), Brigham & Women’s Hospital (USA) and Texas A&M University (USA).

Using advanced tools and AI, the team will focus on studying how splicing impacts the cell’s ability to process genetic information and how this goes wrong in patients with ALS. They will take discoveries from AI through to the final stages of laboratory testing with the goal of progressing new treatments for patients.

The ALS/SPLICE team is a partnership between Entelo (UK) and the University of Sydney (Australia).

Using medical and molecular data from thousands of patients, the team will investigate what causes neurones to go awry in different forms of ALS. They aim to pinpoint targets for potential therapies and look for new and existing medicines that could be used to treat individual patient’s needs.

Schmidt Center ALS Target Team is a partnership between the Eric and Wendy Schmidt Center at the Broad Institute of MIT and Harvard (USA) and colleagues across the Broad Institute, MIT, Harvard, and Mass General Brigham.

ALS destroys connections between neurons and muscles, causing difficulty with movement and speech. Focusing on disruptions in lipid metabolism - the fats that make up nerve cell membranes - as a key driver of ALS progression, the team will search for therapeutic targets that slow and stimulate the repair of these lost connections.

The project is a partnership between biotechnology company Espoir Biosciences (Canada), Cervolve (Canada) and The Early Drug Discovery Unit (Canada).

The team uses artificial intelligence to combine different types of biological and clinical data from people with ALS to identify hidden disease subtypes and the biological changes driving them. We then model how the disease “pushes” cells away from a healthy state to pinpoint the genes and pathways driving this shift, helping us discover more precise drug targets and accelerate personalised treatments for ALS.

The ALS Precision Discovery Consortium is a partnership between King’s College London (UK), GlaxoSmithKline and Bielefeld University (Germany).

Combining their multi-disciplinary skills and tools for drug design and discovery with data from ALS patients, the team will aim to identify entirely novel targets for ALS, leading to faster and more personalised ways to create drug treatments for ALS.

Team La Jolla Labs-Unravel-Ulm is a partnership between La Jolla Labs, Inc. (USA), Unravel Biosciences Inc. (USA) and the University of Ulm (Germany).

The team will use advanced AI and patient data to map ALS subtypes and identify precision treatment targets, emphasizing sporadic ALS - the most common and least understood form of the disease.

MOSAIC ALS is a partnership between Mosaic Neuroscience (USA), the Humphrey Lab at the Icahn School of Medicine at Mount Sinai (USA), GenieUs Genomics (Australia), the Gale Hammell Lab at NYU (USA), and additional collaborators.

ALS damages the nerves that control movement. The team are combining DNA from tens of thousands of people with ALS, layered with how genes actually behave in the body, into a single map of biology. A computer learning system reads that map to find genes most likely to lead to new treatments.

The ALS Genome-Ai Initiative is a partnership between UMass Chan Medical School (USA), the National Institute of Aging, US Government (USA), the University of Massachusetts (USA), NIH (USA), the National Institute of Neurological Disorders and Stroke, and Ohio State University (USA)

Developing an AI-powered engine to analyse human genetics, the team will be able to reveal new drug targets that current methods cannot see, opening the door to new ALS therapies. In partnership with the University of Oxford (UK).

Taking an AI-driven approach to analyse ALS patient datasets, the team aims to uncover common molecular patterns patients share, as well as what makes certain groups different. The results will point to druggable pathways that can be tested quickly to target different ALS patients.

Latitude45 is a partnership between Paris Brain Institute (France), Simmunome (Canada) and Servier (France).

Training an AI system to read the molecular fingerprints of thousands of ALS patients, across their genes, proteins, and cells, to find the biological switches that drive the disease. The team’s goal is to find a shortlist of the most promising targets for future treatments. In partnership with King’s College London (UK).

The team is focused on moving beyond describing sex differences in ALS to systematically resolving their molecular basis, transforming them into actionable targets for precision medicine.

King’s College London (UK) in partnership with Oxford PharmaGenesis (UK), University Medical Center Utrecht (The Netherlands), The University of Exeter (UK) and the DEMON Network (International).

Using powerful AI tools to decode how the ALS protein TDP-43 disrupts gene regulation in the brain, the team at the University of Pennsylvania aims to identify ten new drug targets for the disease. Team member Yentli Soto Albrecht lost her father to ALS in 2024 and carries the same genetic mutation that claimed his life – a mutation that, without a cure, will claim hers as well. This drives everything she does as a scientist and future doctor.

Using an AI model to combine biological data from ALS patients into a connected map or “knowledge graph”, the team will study how genes interact as a system rather than in isolation. Team member Keith Stormo’s ALS symptoms began in 2018. Being a scientist and teacher is what motivated him to build a team for the Longitude Prize on ALS.

Team Stormo is a partnership between the Washington University (USA) and the University of Idaho (USA).

By unifying genetic, molecular, and clinical data in one powerful AI system, the team aims to decode ALS from scratch. They will identify distinct disease forms of ALS, pinpoint the genes that drive them, and deliver up to ten proven targets to help treat ALS.

Vector ALS is a partnership between Translational Neurodegeneration, German Center for Neurodegenerative Diseases, Rostock/Greifswald (Germany) DZNE (the German Center for Neurodegenerative Diseases), Gladstone Institutes (USA), University College London (UK), Katholieke Universiteit Leuven (Belgium), the University of Edinburgh (UK), the National University of Singapore (Singapore) and Stockholm University (Sweden).

Using AI to study patients’ biological data and identify hidden patterns in ALS, the team’s goal is to match each patient with the right ALS therapy earlier, making clinical trials faster and future treatments more effective.

TUM ALIGN ALS is a partnership between TUM Klinikum Rechts der Isar (Germany), the University of Melbourne (Australia), the University of Ulm (Germany), the University of Aachen (Germany), Istituto di Ricerche Farmacologiche Mario Negri IRCCS (Italy), and Raya Therapeutic Inc. (Canada).

Using AI models trained on whole genome sequencing data from ALS patients to test affected cells and proteins against potential candidate drugs. The team’s approach aims to directly link genetic causes of ALS to actionable treatments.

Decode ALS is a partnership between University of Sheffield (UK), Weizmann Institute of Science (Israel), Columbia University (USA) and Yale University (USA).

The team Integrates multi-institutional ALS datasets across genetic layers, using AI to uncover disease patterns that remain invisible when analysed in isolation. The approach aims to better identify drug targets and match them to patients most likely to benefit, accelerating the path to more effective treatments.

Vanderbilt NeuroCline is a partnership between Vanderbilt Health & Vanderbilt University (USA).

In partnership with Google Cloud.